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Abstract
Objective: To assess the clinical features of exodontias performed in cancer patients who have been receiving 
intravenous bisphosphonates (BPs).
Study Design: This is a retrospective cohort study using a sample of 20 patients receiving BPs who had 62 teeth 
extracted. An univariate analysis was applied to calculate socket healing time (HT), comparing among exodontias 
performed according to cause, such as periodontal disease or caries, type of BP, and use of corticosteroid. In order 
to analyze the influence of each variable on HT, multiple statistical analyses were performed through logistic 
multiple regression. 
Results: From the 62 tooth extractions performed, 5 exodontias had evolved to 4 sites of bisphosphonate-related 
osteonecrosis of the jaws (BOJ). Of another 57 exodontias without development of BOJ, HT was significantly 
better for tooth extraction performed in patients receiving corticosteroid (p= .01), for tooth extracted due to caries 
(p= .04), and for extractions under pamidronate (p= .03). Sockets after exodontias due to periodontal diseases 
had OR= 5.22 (95% CI 1.73-133.66, p=0.01) for delayed HT, exodontias performed under corticosteroid use had 
OR=0.04 (95% CI 0.01-0.40, p<0.001), and exodontias performed under zoledronate had OR=0.31 (95% CI 0.08-
1.25, p=0.10).
Conclusions: Exodontias performed in patients under BP therapy had a low rate of BOJ occurrence. Zoledronate 
and periodontal diseases influence delayed socket healing. Adjuvant antibiotics could be relevant procedures 
aimed at reducing the risk of BOJ development. 
Key words: Bisphosphonate; tooth extraction; osteonecrosis; jaw osteonecrosis; bisphosphonate-related 
osteonecrosis; socket healing.
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Introduction
Bisphosphonates (BPs) are compounds characterized 
by two carbon-phosphate bonds, which act on decreas-
ing bone resorption, varying greatly from different 
classes of BPs. According to the presence of nitrogen 
bound to the chemical structure, BPs are classified as 
non-nitrogen BPs, such as etidronate, clodronate, and 
nitrogen BPs, such as risedronate, aledronate, pamidro-
nate, and zoledronate (1). These drugs are widely used 
in the treatment of bone metabolism diseases, notably 
to reduce skeletally related events in patients with meta-
static cancer, multiple myloma, Paget’s disease, and os-
teoporosis (2-4).
Adverse effects related to intravenous BPs generally 
include acute systemic inflammatory reaction, ocular 
inflammation, renal failure, nephrotic syndrome, and 
osteonecrosis of the jaws (5). Bisphosphonate-related 
osteonecrosis of the jaws (BOJ) is defined as a side ef-
fect to the inhibition of osteoclasts in which exposed and 
necrotic bone persisting for more than 8 weeks occurs 
in the maxillofacial region, which could be related to 
current or previous treatment with BPs, with no history 
of radiotherapy to the head and neck area (6). Although 
bone remodeling suppression related to BPs is well es-
tablished, the entire mechanism of BOJ pathogenesis 
remains unclear (7).
Several studies have reported tooth extraction as a po-
tential risk factor for the development of BOJ (6, 8-10). 
The incidence of BOJ associated with exodontias varies 
between 36.7% and 73% of reported cases (11-13). The 
typical presentation is a nonhealing extraction socket or 
exposed jawbone with progression to sequestrum forma-
tion associated with localized swelling and purulent dis-
charge. A couple of prospective cohort studies have es-
tablished a specific preventive protocol for tooth extrac-
tion in patients using BPs with an expressive reduction of 
its occurrence, ranging between 0 and 2.7% (14-18). 
To the best of our knowledge, no study has assessed the 
socket healing time (HT) after exodontias have been 
performed in patients under bisphosphonate therapy. 
Thus, the aim of the current study was to evaluate socket 
healing after exodontias in these patients. 
Material and Methods
-Study design and sample constitution
This research consisted of a retrospective observational 
cohort study in which exodontias performed in patients 
using BPs due to reduce the skeletally related events in 
patients with bone metastases were evaluated. A total 
of 20 patients met the criteria for inclusion. Sixty-two 
exodontias, performed between January 2004 and 
December 2010 at the Stomatology Department of 
Hospital A.C. Camargo, São Paulo, Brazil. The study 
was approved by the ethical committee of the institution 
and registered under protocol 1512/2011.
-Research criteria
Inclusion criteria consisted of patients who submitted 
to tooth extraction and who had received at least one 
application of intravenous BP. 
Exclusion criteria consisted of patients who underwent 
radiotherapy in the region of head and neck. Futhermore, 
cases of tooth extractions performed in consequence 
of previous osteonecrosis related to BPs were also 
excluded.
-Data collected
The patient’s information was obtained from medical 
charts. Data were collected on gender, age, underlying 
disease, use of corticosteroid and duration of its 
administration, type of BP and doses administered, 
date of last BP infusion, antibiotic administration, teeth 
extracted, date and motive of exodontia, as well as date 
of alveolar socket healing. 
Alveolar socket evaluation
The socket status after exodontias was classified into 
two forms:
- Healed socket: alveolar socket had been totally 
recovered by the mucosa and there was no osseous 
exposed or suppuration.
- Non-healed socket: during the follow-up period, the 
socket had no sign of healing. Consequently, bone 
exposure or local infection (pus drainage) could be 
observed.
All patients were seen once a week and the socket 
healing time (HT) was also assessed. The HT was 
established as the period between the exodontias and 
the complete healing of the socket. The clinical aspects 
for non- healed socket can be observed in figure 1. 
Furthermore, only the cases which had healed socket 
were included for analysis of the HT. 
Fig. 1. Non-healed socket after exodontia. A. Panoramic radiograph 
before exodontia. B. Panoramic radiograph after 3 months of exo-
dontia; image suggests bone remodeling did not occurred in alveolar 
socket. C. Clinical aspect of alveolar socket after exodontia without 
mucosa coverage.
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-Statistical Analysis
Bivariate analysis was performed using the Mann-
Whitney U test to analyze the differences on HT 
according to the type of BPs (pamidronate or 
zoledronate), corticosteroid, and motive of exodontia. 
Time of BP interruption was established through 
the interval of days between the date of the last BP 
infusion to the date of exodontia. This interval was 
correlated with HT in order to evaluate the influence of 
its interruption on the alveolar socket healing, through 
the Person’s Correlation Test. In order to analyze the 
influence of each variable (cause of exodontia, type 
of BPs, corticosteroid use) on HT, risk estimation was 
established for overdelayed socket healing through 
multiple logistic regression.
Results
-General Results 
The sample consisted of 20 patients who were submitted 
to 62 tooth extractions. The median age was 62.2 years, 
ranging from 43 to 83 years, with 80% of the patients 
being women. Most of the patients were using BPs due 
to bone metastases of breast cancer (Table 1).
Variables Category N (%) 
Gender Female Male 
16 (80%) 
04 (20%) 
Age (years) Median Range
62.2 
43-83
Underlying diseases 
Breast Cancer 
Multiple Myeloma 
Prostate Cancer 
Non-Hodgkin Lymphoma 
11 (55%) 
05 (25%) 
03 (15%) 
01 (05%) 
Bisphosphonate
Zoledronate (median time=5 months range 1-60 months) 
Pamidronate (median=13 months range 1-85 months) 
Zoledronate/Pamidronate 
14 (65%) 
06 (30%) 
01 (05%) 
Corticoids NoYes
11 (55%) 
09 (45%) 
Tooth extraction 
Total 
Range
Median by patient 
62
1-10
2
Table 1. Clinical features of the 20 patients submitted to exodontias and using bisphosphonates.
A total of 62 teeth were extracted, 26 on the maxilla and 
36 on the mandible. The median of dental extraction by 
patient was 2 teeth, ranging from 1 tooth to 10 teeth. 
Regarding BP type, 37 teeth were extracted in patients 
under zoledronate therapy and 25 under pamidronate. 
In addition, 29 teeth were extracted due to periodontal 
disease and 33 due to caries. For all exodontias, antibiotic 
adjuvant therapy was used, with 34 teeth extracted 
under amoxicillin, 22 amoxicillin and metronidazole, 
and 6 teeth extracted under clindamycin. Antibiotics 
were initiated one day prior to tooth extraction and the 
mean time of antibiotic therapy was 8.41+2.99 days.
A total of 34 exodontias were performed under 
corticosteroid use, 10 patients were receiving oral doses 
of dexamethasone which ranged from 20-40mg a day. The 
prescriptions had been performed due to the management 
of osseous pain related to bone metastases. The mean 
time of corticosteroid use was 11 months (median of 3 
months, ranging from 1 month to 23 months). 
-Bisphosphonate-related Osteonecrosis of the Jaws 
BOJ associated to tooth extraction was observed in 
4 patients. Interestingly, all osteonecrosis sites were 
related to premolar extractions. One patient had been 
submitted to 2 exodontias in the same clinical session 
(teeth 44 and 45) and both teeth were extracted due 
to periodontal disease. The other three patients who 
developed BOJ had their teeth extracted due to carie (2 
cases) and periodontal diseases (one case). With regard 
to BP type, 3 out of 4 patients were using zoledronate 
and the other patient was using pamidronate. The mean 
dose of BP was 18, ranging from 10 to 40 doses.
-Alveolar socket healing
Of the 16 patients without BOJ development, 11 were 
using zoledronate and 5 pamidronate (median of BP 
doses was 7, ranging from 1 to 85 doses). 
Of the 62 exodontias, 57 had healed alveolar socket at a 
median healing time of 27 days (mean 30.49+16.49, range 
7-71 days). The exodontias performed due to caries had 
their sockets healed at a median HT of 24 days (mean 
27.35±16.33, range 7 to 58 days), whereas the sockets 
related to exodontias due to periodontal disease healed 
at median HT of 32 days (mean 34.23±16.18, range 11-71 
days) (Fig. 2).
Concerning the type of BP, exodontias in patients 
using pamidronate had a median HT of 24 days (mean 
26.54±19.06, range 7 to 71 days), whereas in patients 
using zoledronate the median HT was 33 days (mean 
33.36±13.93, range 14 to 65 days) (Fig. 2). Furthermore, 
patients receiving therapy with corticosteroid also 
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had lower HT than non-corticosteroid patients, with a 
median HT of 22 days (mean 24.93±11.15 days) and 42 
days (mean 36.25±19.16 days), respectively (Fig. 2). The 
mean time of the interval between the last BP dose to 
the date of the exodontia was 64.27 days (median of 36, 
ranging from 8 to 877 days). There was no correlation 
among this interval with HT (Fig. 2) (r=0.25; p=0.03). 
According to the healing outcomes, 34 sockets were 
classified as expected socket healing in which HT 
ranged between 7 and 28 days, whereas 23 sockets were 
classified as delayed socket healing in which HT ranged 
between 36 and 71 days. Sockets after exodontias due 
to periodontal diseases presented OR=15.22 (95% CI 
1.73-133.66, p=0.01) for delayed socket healing time 
compared with socket healing after exodontias due to 
caries, whereas sockets after exodontias performed 
under corticosteroid use had OR=0.04 (95% CI 0.01-
0.40, p<0.001) compared with sockets with delayed 
healing after exodontias not under corticosteroid use. 
Furthermore, socket healing after exodontias performed 
under zoledronate had OR=0.31 (95% CI 0.08-1.25, 
p=0.10) compared with socket healing after exodontias 
performed under pamidronate (Table 2). 
Discussion
Suppression of bone turnover may be part of the 
pathophysiology of BOJ development (7,19). The basic 
premise of this hypothesis is that jaw bones have a high 
remodeling rate compared with other bones. However, 
Fig. 2. Univariate analysis of socket healing time (HT). Fig2a. Boxplot describing HT according to motive of exodontia. Fig2b. Boxplot describ-
ing HT according to type of BP. Fig2c. Boxplot describing HT according to corticosteroid use. Fig2d. Correlation between Socket healing time 
(HT) and period among last BP infusion to exodontia. 
 OR (95% CI) p value 
Motive of exodontia 15.22 (1.73-133.66) 0.01 
Corticosteroid use 0.04 (0.01-0.40) <0.001 
Type of BP 0.31 (0.08-1.25) 0.10 
Table 2. Estimative for occurrence of delayed socket healing 
time according to the variables analyzed through logistic regres-
sion model.
Note: Design of variables: motive of exodontia: 0=carie, 
1=periodontal diseases; corticosteroid use: 0=no use, 1=had 
used; type of BP: 0=pamidronate; 1=zoledronate.
Abbreviations: OR, odds ratio; CI, confidence interval. 
Med Oral Patol Oral Cir Bucal. 2013 Jul 1;18 (4):e650-6.                                                                                                                     Socket healing in patients undergoing bisphosphonate therapy
e654
BPs can diminish or inhibit bone turnover according to 
its potency and mechanism of action. Non-nitrogen BPs 
inhibit bone resorption by incorporation into cytotoxic 
adenosine triphosphate (ATP) analogues, whereas the 
mechanism of action of nitrogen BPs is related to its 
interactions with reactions such as mevalonate pathway, 
interfering with post-translational prenylation of proteins 
by a decrease of the formation of isoprenoid lipids 
such as farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate, which affect cellular activity such as 
apoptosis in several cell types, including osteoclasts 
(1,2,20). Differences in potencies and binding affinities 
among BPs are known to affect the degree of remodeling 
suppression, as well as the dose and duration of BP 
therapy (7,21). Furthermore, zoledronate is considered 
the most potent BP. In the present study, 6 out of 20 
patients were using pamidronate, and these patients 
had been submitted to 25 exodontias with one socket 
developing BOJ. Additionally, the other 13 patients 
were using zoledronate and were submitted to 36 
exodontias, in which 3 had evolved to BOJ. A single 
patient was firstly treated by zoledronate and substituted 
by pamidronate due to kidney failure. This patient was 
submitted to one exodontia without BOJ development. 
Bagan et al. (2009) pointed that BOJ is more related 
to previous dental extractions than to its spontaneous 
occurrence (22). Epithelialization is an essential step 
in post-intervention wound healing and it has been 
suggested that high doses of BPs have direct toxic effects 
on the oral epithelium. In addition, BPs can also inhibit 
normal healing of soft tissue lesions caused by either 
dental intervention or some other trauma, which would 
result in exposure of the bone prior to necrosis due to 
the release of BP from the adjacent injured bone (7,19). 
The present study criteria considered the term ‘socket 
healing’ as the socket totally covered by the mucosa, 
independently of bone formation. Besides the 57 sockets 
which had complete healing, the mean and median of 
HT were 30 and 27 days, respectively. Exodontias in 
patients under zoledronate had healed at a median of 33 
days, whereas sockets under pamidronate had healed at 
median HT of 24 days. This difference was statistically 
significant through univariate analysis. Consequently, 
our results suggest that zoledronate interferes more in 
the socket healing process than pamidronate. Moreover, 
the mean time of the zoledronate use was lower than 
pamidronate. The influence of zoledronate in bone 
turnover was evaluated in beagle-dogs (21). The authors 
showed that the use of zoledronate for 6 months had 
produced nearly complete suppression (99%) on bone 
remodeling of the mandible. This scientific evidence 
highlighted that zoledronate interferes with bone 
remodeling and may also explain the delayed socket 
healing after exodontias were performed in patients 
under zoledronate therapy.
It is known that the BP nucleus carries a strong negative 
charge as a result of the clustering of oxygen atoms in 
the two phosphate groups, and thus, binds tightly to 
the positively charged surface of hydroxyapatite. As 
a consequence, incorporation into the bone mineral 
remains in the bone over a period of years (23). In 
the present study, the influence of BP interruption 
was calculated according to Pearson’s correlation test 
and there was no relation to the HT (r=.25). However, 
Saia et al. developed a preventive protocol for tooth 
extraction in patients under a duration time of 3 years 
on nitrogen-BPs therapy (16). The authors recommend 
BP interruption for 1 month after exodontias. In fact, 
there is no scientific evidence that BP interruption could 
promote better socket healing and more studies are 
necessary regarding this issue. 
We reviewed the literature and found 5 other studies 
assessing exodontias in patients under BP therapy 
(Table 3) (14-18). BOJ incidence ranged from 0 to 
8.0%. In general, most of these studies recommend 
antibiotics as adjuvant therapy to perform the exodontia 
(15-18). Antibiotic adjuvant may be an important 
procedure to reduce the bacterial colonization of oral 
cavity and may also prevent BOJ occurrence as well 
as opportunistic bacterial infections at sockets after 
Studies Study design Patients Exodontias Antibiotics adjuvant BOJ (%) 
Regev et al., 2008 Prospective 10 15 Data not shown 0 (0) 
Lodi et al., 2010 Prospective 23 38 20 days (3 days before exodontia and 17 after) 0(0)
Saia et al., 2010 Prospective 60 185 
if pain 7 days before exodontia 
and 7 after 
if no pain 7 days after exodontia 
    5 (2.7) 
Ferlito et al., 2011 Prospective 43 102 7 days (2 days before exodontia and 5 after) 0 (0) 
Scoletta et al., 2011 Prospective 64 220 6 days (1 day before exodontia and 5 after) 5 (2.27) 
Present Study Retrospective 20 62 8.41+2.99 days after exodontia  5 (8.06) 
Table 3. Literature review of studies that evaluated exodontias in patients using bisphosphonates.
BOJ: Bisphosphonate-related osteonecrosis of the jaws.
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exodontias. Differently, Regev et al. (14) standardized 
tooth extraction with orthodontic elastics. The tooth 
was exfoliated in order to minimize inherent trauma 
related to exodontias; antibiotic prescription as adjuvant 
therapy was not mentioned. 
An interesting data found in the present study was a 
difference between HT in exodontias performed due to 
caries (median HT of 24 days) and periodontal diseases 
(median HT of 32 days) (p=.04). Multiple analysis also 
confirmed that periodontal diseases increase HT of sockets 
after exodontias (OR 15.22; 95% CI 1.73-133.66, p=0.01). 
Therefore, exodontias due to periodontal diseases needed a 
major time to heal and, consequently, the socket would be 
more susceptible to infection due to oral pathogens. 
For the present casuistic, exodontias were performed due 
to advanced periodontal diseases without possibilities 
of conservative treatment or unrestorable teeth related 
to caries. Periodontal diseases can be defined as 
complex bacteria-induced infections characterized by 
an inflammatory host response to plaque microbiota 
and their products. These microorganisms have 
virulence factors capable of causing massive tissue 
destruction both directly, through tissue invasion and 
the production of harmful substances, or indirectly, 
by activation of host defense mechanisms, creating an 
inflammatory infiltrate with potent catabolic activity 
that can interfere with normal host defense mechanisms. 
Then, this manifestation depends on an interaction 
between environmental, microbiologic agent and host-
related factors (24). On the other hand, dental caries 
are characterized by the focal destruction of dental 
mineralized structures such as enamel and dentin due 
to colonization by acidogenic and acidophilic bacteria. 
Additionally, the degree and severity of the infection 
presented prior to exodontia are higher for teeth extracted 
due to periodontal diseases. Periodontal diseases could 
be characterized by intense tissue destruction due to 
inflammatory response, as well as bacteria production 
of harmful substances. At the same time, it is noted that 
exodontias, due to periodontal diseases, reported higher 
HT and is described as a factor for delayed HT.
Exodontias under corticosteroid use is also observed 
to have presented lower HT confirmed by bivariate 
analysis, and reduced HT according to a multiple 
analysis. Despite the fact that corticosteroid use for a 
longer period promotes an immunological side effect, it 
could not be denied that corticosteroids are potent anti-
inflammatory drugs with good affinity at oral cavity 
tissues. Dental extractions are surgical procedures 
that involve inherent trauma caused by the technical 
manipulation of the oral soft tissue, the remaining 
tooth and the alveolar socket bone. All the teeth were 
extracted with the most adequate techniques for an 
atraumatic tooth extraction using mainly elevators 
and forceps (if necessary). However, inherent trauma 
involves an inflammatory response that probably was 
reduced for patients using corticosteroid due to medical 
prescription. Paradoxically, the fact that corticosteroid 
use could improve HT after exodontias under BPs, 
all 4 cases of BOJ occurrence after exodontias were 
performed under corticosteroid use at a mean time 
of 6.2 months (range 1 to 16 months). Adjuvant anti-
inflammatory drugs may be an important procedure to 
reduce inflammation due to inherent trauma of tooth 
extraction, as well as due to the proper pathological 
process that makes tooth extraction necessary.
In conclusion, exodontias performed in patients under 
BP therapy had a low rate of BOJ occurrence. Indeed, 
socket healing after exodontias happened in delayed 
healing time, mostly, in exodontias due to periodontal 
diseases and under zoledronate use. Therefore, the 
prescription of adjuvant antibiotics and modulators of 
inflammation could be important procedures aiming 
to reduce the healing time of exodontias performed 
in patients under BP. Moreover, from our viewpoint, 
exodontias, when necessary, must be performed by 
expert dentists and follow-up must occur until the 
complete covering of the socket by mucosa. 
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